<DOC>
	<DOC>NCT00210041</DOC>
	<brief_summary>The purpose of this study is to determine whether association Gemcitabine-Cisplatin is effective in the treatment of penis epidermoid carcinoma loco-regionally advanced or metastatic.</brief_summary>
	<brief_title>Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Genital Neoplasms, Male</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Age ≥ 18 years OMS ≤ 2 Penis epidermoid carcinoma histologically proved. Tumor with ganglionic locoregional injury inextirpable and/or metastatic (M1, all T , all N), at initial diagnostic or at relapse after first treatment with curative aim (surgery and / or radiotherapy) Disease measurable with RECIST criteria Absence of all former chemotherapy during 5 years between inclusion. If former radiotherapy, necessity to have appreciated targets outside the irradiation fields. If former radiotherapy, it must have been done more than 4 weeks before inclusion in the study. Biologicals values required : polynuclear neutrophils ≥ 1500/mm3, bloodplatelets ≥ 100000/mm3, Hb ≥ 10 g/dl, Transaminases &lt; 3N, TP ≥ 70%, total bilirubin &lt; 1,5 N, creatinine in the blood ≤ 110 micromoles/l. Normal clearance of creatinine, according to Cockroft and Gault's formulae. Calcemia : normal or anomaly without clinical meaning. Wellinformed written consent, signed by the patient. Uncontrolled cerebral known metastasis All former chemotherapy administration during 5 years between inclusion Other cancer (except basocellular cancer of skin correctly treated, or cancerous disease considered with good prognosis and on remission until 5 years at least) Uncontrolled cardiac insufficiency or all other severe and uncontrolled pathology. Peripheric neuropathy ≥ grade 2 OMS Anormal audiogram Patient difficult to follow for geographical, psychological or family reasons. Persons protected by law.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Genital Neoplasms, Male</keyword>
</DOC>